B-cell lymphoma 6 messenger RNA 3' untranslated region (BCL6 mRNA 3'UTR)

The B-cell lymphoma 6 (BCL6) mRNA 3' untranslated region (3'UTR) is a critical regulatory segment of the BCL6 transcript, which encodes a master transcriptional repressor essential for germinal center formation and B-cell development [1.1.2, 1.3.1]. This region contains numerous regulatory elements, including AU-rich elements and binding sites for microRNAs such as the miR-30 family, miR-155, and miR-9, which collectively control BCL6 expression levels post-transcriptionally [1.3.3, 1.5.1]. In many B-cell lymphomas, particularly diffuse large B-cell lymphoma (DLBCL), the 3'UTR is frequently mutated or deleted, leading to the loss of these negative regulatory controls and subsequent oncogenic overexpression of the BCL6 protein [1.3.2, 1.3.3]. This overexpression drives malignancy by repressing DNA damage checkpoints and preventing terminal B-cell differentiation [1.4.1, 1.4.3]. As a therapeutic target, the BCL6 mRNA 3'UTR is being explored through the use of antisense oligonucleotides (ASOs) and RNA interference (RNAi) strategies designed to degrade the mRNA or inhibit its translation [1.2.1, 1.4.2]. These approaches aim to restore normal cellular checkpoints and induce apoptosis in malignant cells by reducing BCL6 oncoprotein levels [1.4.2]. However, therapeutic challenges include the effective delivery of oligonucleotide-based drugs and the risk of systemic inflammation, as BCL6 is a vital negative regulator of inflammatory responses in various tissues [1.4.1].

Other names

BCL6 3'UTRB-cell CLL/lymphoma 6 3' untranslated regionBCL6 3-prime untranslated regionBCL6 3' untranslated region

Induction of RNase H-mediated mRNA degradation, inhibition of translation, or blocking of regulatory protein/miRNA binding sites to modulate BCL6 protein levels [1.2.1, 1.4.2].